Pharmacokinetics of crizotinib in NSCLC patients

Expert Opinion on Drug Metabolism & Toxicology
Gerhard HamiltonOtto Burghuber

Abstract

For a subpopulation of NSCLC patients genetic rearrangement of the anaplastic lymphoma kinase (ALK) was found as driver mutation, which can be targeted by the selective inhibitor crizotinib. This article presents an overview of the clinical studies that provided the characterization of the pharmacokinetic parameters for the administration of crizotinib to cancer patients and the factors influencing the clinical profiles of this drug. Crizotinib is administered orally as a capsule and clinical studies indicated 250 mg crizotinib BID continuously as the maximal tolerated dose in cancer patients. Bioavailability is ∼ 40% and pharmacokinetic parameters are influenced by food only to a minor degree. This dose of the drug corresponds to a significant inhibition of the mutated ALK, retards tumor growth and achieves clinical responses in the majority of patients. Crizotinib lactam is the single metabolite with minor inhibitory activity for the ALK fusion protein. Metabolization is executed mainly by CYP3A4/5 and is modulated by other drugs interacting with this cytochrome oxidase. Despite the one-fits-all approach in administration of crizotinib at a fixed dose the pharmacokinetic parameters indicate a stable steady state upon continuo...Continue Reading

References

Mar 6, 2008·Neoplasia : an International Journal for Oncology Research·Sven PernerMark A Rubin
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T Shaw, Jeffrey A Engelman
Mar 15, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Denis MailletMaurice Pérol
May 21, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Andrew Timm, Jill M Kolesar
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Aug 16, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Young Hak KimMichiaki Mishima
Oct 5, 2013·Clinical Pharmacology and Therapeutics·B SolomonA T Shaw
Feb 28, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shakun M MalikRichard Pazdur
Apr 8, 2014·Genes·Debra J H Mathews, Leila Jamal
Apr 24, 2014·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·David F Heigener, Martin Reck
Jun 24, 2014·Genes & Cancer·Rodney E ShackelfordJames Cotelingam
Jun 29, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin YangSiqi Han
Jul 2, 2014·Nature Reviews. Clinical Oncology·D Ross CamidgeLecia V Sequist
Jul 6, 2014·Clinical Lung Cancer·Gouji Toyokawa, Takashi Seto
Aug 26, 2014·Expert Review of Anticancer Therapy·Christian RolfoLuis Raez
Oct 25, 2014·Therapeutic Advances in Medical Oncology·Thomas E Stinchcombe
Jan 21, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daniela IaconoLucio Crinò

❮ Previous
Next ❯

Citations

Dec 15, 2015·Expert Review of Anticancer Therapy·Ittai B MullerGodefridus J Peters
May 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·Godefridus J Peters, Richard J Honeywell
Nov 4, 2016·Expert Review of Anticancer Therapy·Srividya SrinivasamaharajCesar A Perez
Apr 4, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Gaby A M EliesenRick Greupink
Mar 28, 2017·Cancer Treatment Reviews·Francesco FacchinettiMarcello Tiseo
Jul 2, 2017·Journal of Clinical Pharmacy and Therapeutics·S WangZ Yang
Feb 1, 2019·British Journal of Clinical Pharmacology·Bruno RevolAnne-Claire Toffart
Dec 20, 2017·Current Opinion in Oncology·Alesha A Thai, Benjamin J Solomon
May 21, 2020·Drug Design, Development and Therapy·Dehua ZhaoJisheng Wang
Oct 22, 2020·Archives of Toxicology·Gaby A M EliesenRick Greupink
Nov 20, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Wenying ShuJia Li
Sep 22, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A A Thai, B J Solomon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Daniel B CostaK D Wilner
Expert Opinion on Pharmacotherapy
Gabriele MinutiFederico Cappuzzo
Expert Opinion on Pharmacotherapy
Lorenza Landi, Federico Cappuzzo
© 2022 Meta ULC. All rights reserved